Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded down 19.4% on Thursday . The stock traded as low as C$0.14 and last traded at C$0.15. 519,694 shares traded hands during trading, a decline of 1% from the average session volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Performance
The stock has a market cap of C$25.50 million, a P/E ratio of -5.10 and a beta of 0.20. The firm’s 50-day moving average is C$0.20 and its two-hundred day moving average is C$0.12. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Insider Trades May Not Tell You What You Think
- DuPont’s Electronics Spinoff: The Start of Something Big
- What Are Dividends? Buy the Best Dividend Stocks
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
- The How and Why of Investing in Gold Stocks
- Market Shift: These 3 Stocks Are Winning While Big Tech Lags
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
